Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Urology ; 177: 202, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37328339
2.
Urology ; 177: 197-203, 2023 Jul.
Article in English | MEDLINE | ID: mdl-37119979

ABSTRACT

OBJECTIVE: To determine the cost-effectiveness of mesh placement in patients undergoing ileal conduit urinary diversion for bladder cancer. Long-term studies have shown that parastomal hernias (PSH) occur in more than half of all stomas. Mesh prophylaxis has been shown to reduce PSH after end-colostomy and ileal conduits. However, no cost-effectiveness studies on mesh prophylaxis have been performed for this population. METHODS: We created a Markov model incorporating the costs and effectiveness of mesh prophylaxis for patients undergoing radical cystectomy and ileal conduit construction. Costs were obtained from the literature and adjusted to 2022 US dollars. Effectiveness was measured in quality-adjusted life years (QALY). 1- and 2-way sensitivity analyses were performed to test the robustness of our model. RESULTS: In stage I-IV bladder cancer, prophylactic mesh placement was costlier, but more effective in providing quality of life compared with no mesh placement at index surgery. Average incremental cost between the 2 strategies across all stages was an additional $897 when mesh was utilized. Incremental effectiveness averaged 0.49 additional QALY across all stages. This resulted in an incremental cost-effectiveness ratio of $2114.71/QALY. Sensitivity analyses indicated that benefit of mesh placement was sensitive to the probability of mesh infection. CONCLUSION: In patients undergoing ileal conduit urinary diversion for bladder cancer, mesh prophylaxis at the time of radical cystectomy is an overall cost-effective strategy in preventing PSH for patients presenting with all stages of bladder cancer.


Subject(s)
Incisional Hernia , Urinary Bladder Neoplasms , Urinary Diversion , Humans , Cost-Effectiveness Analysis , Quality of Life , Cystectomy , Incisional Hernia/surgery , Urinary Bladder Neoplasms/surgery , Surgical Mesh
3.
Medicine (Baltimore) ; 101(46): e31734, 2022 Nov 18.
Article in English | MEDLINE | ID: mdl-36401433

ABSTRACT

RATIONALE: Myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) is one of auto-immune demyelinating diseases of nervous system. Although both regional anesthesia and general anesthesia has been successfully performed in the patient with demyelinating diseases of nervous system, it has been controversial which one is better. PATIENT CONCERNS: Forty-four male patient was admitted for arthroscopic elbow surgery due to limitation of range of motion. The patient was diagnosed as MOGAD with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, and steroid was used to prevent and treat symptoms and signs. DIAGNOSIS: He was diagnosed as MOGAD with anti-NMDA receptor encephalitis, 1 year ago. The patient complaint of dizziness, diplopia, nausea, vomiting, seizure, general weakness and so on when he was confirmed as MOGAD with anti-NMDA receptor encephalitis. The diagnosis of MOGAD was confirmed with positive anti-myelin oligodendrocyte glycoprotein (MOG) Immunoglobulin (Ig)G and negative anti-aquaporin 4 (AQP4) IgG in the blood. INTERVENTIONS AND OUTCOMES: After steroid cover, total intravenous anesthesia (TIVA) with remimazolam and remifentanil was established for the patients. Rocuronium was administered under monitoring of neuromuscular blockade, using train of 4 (TOF). The operation was performed without any event under right lateral decubitus position. The patient was uneventfully recovered from anesthesia. LESSONS: The case report showed total intravenous anesthesia with remimazolam and remifentanil under proper monitoring was successfully performed in the patient with MOGAD.


Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis , Demyelinating Diseases , Male , Humans , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/drug therapy , Remifentanil , Autoantibodies , Myelin-Oligodendrocyte Glycoprotein , Anesthesia, General , Oligodendroglia
4.
Medicine (Baltimore) ; 101(35): e30208, 2022 Sep 02.
Article in English | MEDLINE | ID: mdl-36107606

ABSTRACT

Postherpetic neuralgia (PHN) is the most common complication of herpes zoster, whereas postherpetic pruritus (PHP) a rare one. Although PHN has been extensively studied, few studies have investigated PHP. The purpose of this study was to investigate PHP incidence and associated factors in patients with PHN. This was a retrospective study of patients with PHN. A total of 645 patients were included. This study conducted in a single university hospital. Data included age, sex, height, weight, pain score, PHN site, medications, nerve blocks, and pulsed radiofrequency treatment. Data also included PHP onset and duration among those with PHP. We divided patients into 2 groups: the control group (group C), comprising those without PHP, and pruritus group (group P), comprising those with PHP. The correlation of PHP with other factors was analyzed. Of 207 patients, 58 were in group P whereas 149 in group C. The mean onset time and duration of PHP were 96.5 and 278.6 days, respectively. Pain scores were lower in group P than in group C after 3 and 4 months following vesicle formation. Patients with PHN in the trigeminal nerve had a higher incidence of PHP compared to those with PHN in others. Twenty-eight percent of patients with PHN developed PHP. At 3 and 4 months after vesicle formation, patients with PHP had greater pain improvement compared to those without. Patients with PHN in the trigeminal nerve also had a higher incidence of PHP compared to others.


Subject(s)
Herpes Zoster , Neuralgia, Postherpetic , Herpes Zoster/complications , Herpes Zoster/epidemiology , Herpes Zoster/therapy , Humans , Neuralgia, Postherpetic/epidemiology , Neuralgia, Postherpetic/etiology , Neuralgia, Postherpetic/therapy , Pain Clinics , Pruritus/epidemiology , Pruritus/etiology , Retrospective Studies
5.
Urology ; 164: 177, 2022 06.
Article in English | MEDLINE | ID: mdl-35710169
6.
Urology ; 164: 169-177, 2022 06.
Article in English | MEDLINE | ID: mdl-35218864

ABSTRACT

OBJECTIVE: To determine exposure rates to antibiotics prior to radical cystectomy and determine if there is correlation with post-operative infections. METHODS AND MATERIALS: 2248 patients were identified in the 2016 SEER-Medicare linkage who underwent radical cystectomy between 2008 and 2014 with complete prescription information. An outpatient prescription for an antibiotic within 30 days prior to cystectomy was considered exposure. Antibiotic class and combinations were recorded. Postoperative infectious diagnoses and readmissions were tabulated within 30 days of cystectomy. RESULTS: Fifty one percent of patients (n = 1149) were prescribed an outpatient antibiotic prior to cystectomy. Patients receiving antibiotics were more likely to be female (31% vs 25%, P < .01) and had been diagnosed with an infection (17% vs 11%, P < .01). Antibiotic bowel prophylaxis was prescribed to 42% of patients receiving antibiotics. Postoperatively, the exposure group had higher rates of any infection, (56% vs 51% P < .01) and UTI (36% vs 31% P < .01). All-cause readmission within 30 days was higher in the exposure cohort (26% vs 22%, P = .02) Multivariable logistic regression showed outpatient preoperative antibiotics were an independent risk factor for any infection (HR 1.19, P < .05) and readmission (hazards ratio 1.24, P = .03) in the 30 days after radical cystectomy. CONCLUSION: Outpatient antibiotic use prior to radical cystectomy is common and may be associated with increased risk of postoperative infection and readmission. Antibiotic use prior to radical cystectomy should be examined as a modifiable factor to decrease post-operative morbidity.


Subject(s)
Cystectomy , Urinary Bladder Neoplasms , Aged , Anti-Bacterial Agents/therapeutic use , Cystectomy/adverse effects , Female , Humans , Incidence , Male , Medicare , Postoperative Complications/surgery , Retrospective Studies , United States/epidemiology , Urinary Bladder Neoplasms/drug therapy
7.
Int J Mol Sci ; 22(14)2021 Jul 13.
Article in English | MEDLINE | ID: mdl-34299098

ABSTRACT

BACKGROUND: This study was designed to investigate the effect of cluster differentiation (CD)39 and CD73 inhibitors on the expresion of tumour-associated macrophages (TAMs), M1- versus M2-tumour phenotypes in mice with colon cancer. METHODS: An in vivo study of co-culture with colon cancer cells and immune cells from the bone marrow (BM) of mice was performed. After the confirmation of the effect of polyoxotungstate (POM-1) as an inhibitor of CD39 on TAMs, the mice were randomly divided into a control group without POM-1 and a study group with POM-1, respectively, after subcutaneous injection of CT26 cells. On day 14 after the injection, the mice were sacrificed, and TAMs were evaluated using fluorescence-activated cell sorting. RESULTS: In the in vivo study, the co-culture with POM-1 significantly increased the apoptosis of CT26 cells. The cell population from the co-culture with POM-1 showed significant increases in the expression of CD11b+ for myeloid cells, lymphocyte antigen 6 complex, locus C (Ly6C+) for monocytes, M1-tumour phenotypes from TAMs, and F4/80+ for macrophages. In the in vivo study, tumour growth in the study group with POM-1 was significantly limited, compared with the control group without POM-1. The expressions of Ly6C+ and major histocompatibility complex class II+ for M1-tumour phenotypes from TAMs on F4/80+ from the tumour tissue in the study group had significantly higher values compared with the control group. CONCLUSION: The inhibition of CD39 with POM-1 prevented the growth of colon cancer in mice, and it was associated with the increased expression of M1-tumour phenotypes from TAMs in the cancer tissue.


Subject(s)
Apyrase/antagonists & inhibitors , Colonic Neoplasms/prevention & control , Polymers/pharmacology , Tumor-Associated Macrophages/drug effects , Tungsten Compounds/pharmacology , Animals , Antigens, CD , Apoptosis , Cell Proliferation , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Humans , Mice , Mice, Inbred BALB C , Prognosis , Tumor Cells, Cultured , Tumor-Associated Macrophages/metabolism , Tumor-Associated Macrophages/pathology , Xenograft Model Antitumor Assays
8.
Int J Med Sci ; 17(18): 2941-2946, 2020.
Article in English | MEDLINE | ID: mdl-33173414

ABSTRACT

Background: Genetic variations of mu-opioid receptors are well known to contribute to growth and progression of tumors. The most common single-nucleotide polymorphism (SNP) in the mu-opioid receptor 1 gene (OPRM1) is the A118G mutation. We examined the association between the recurrent breast cancer and genotypes of OPRM1 A118G SNP (AA vs. AG vs. GG) in Korean women population. Methods: We analysed medical records and genetic data of 200 patients aged more than 20 who underwent primary breast cancer surgery from June 2012 to June 2014 and diagnosed recurrent breast cancer from June 2012 to September 2019. Results: The incidence of recurrent breast cancer was 6.1%, 8.2%, and 4.8% in genotype AA, AG and GG, respectively (p=0.780). The incidence of recurrent breast cancer in volatile anaesthesia group was 7.0% and 7.1% in total intravenous anaesthesia (TIVA) group (RR = 0.984, 95% CI = 0.328 - 2.951; p = 0.978). Conclusion: OPRM1 A118G SNP had no influence on breast cancer recurrence in Korean women. Anaesthesia technique did not show significant effect on the incidence of recurrent breast cancer.


Subject(s)
Breast Neoplasms/surgery , Neoplasm Recurrence, Local/epidemiology , Receptors, Opioid, mu/genetics , Adult , Aged , Anesthesia, Inhalation/statistics & numerical data , Anesthesia, Intravenous/statistics & numerical data , Breast/pathology , Breast/surgery , Breast Neoplasms/genetics , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Female , Humans , Incidence , Kaplan-Meier Estimate , Mastectomy/adverse effects , Middle Aged , Neoplasm Recurrence, Local/genetics , Polymorphism, Single Nucleotide , Republic of Korea/epidemiology , Retrospective Studies , Risk Assessment/methods , Risk Assessment/statistics & numerical data , Treatment Outcome
9.
Urology ; 124: 264-270, 2019 02.
Article in English | MEDLINE | ID: mdl-30786981

ABSTRACT

OBJECTIVE: To determine the impact of concurrent inflatable penile prosthesis (IPP) and artificial urinary sphincter (AUS) implantation on perioperative complications and long-term device survival, among men with postprostatectomy erectile dysfunction and urinary incontinence. METHODS: We identified men older than 65 treated with radical prostatectomy in the Surveillance, Epidemiology, and End Results Medicare database between 2002 and 2016. IPP or AUS placement was determined by current procedural terminology (CPT) code, with dual implantation (DI) defined as IPP and AUS placement on the same date. Device survival was assessed using CPT codes for device removal, replacement, and/or repair. Complications were assessed within 90 days using ICD-9 codes. Statistical analysis was performed using SAS v9.3 (Cary, NC). RESULTS: A total of 37,599 men underwent radical prostatectomy, with AUS placed in 793 (2.1%), IPP placed in 644 (1.7%), and DI in 62 (0.2%). Relative to AUS placement alone, men undergoing DI were younger (68.8 vs 70.2 years, P = 0.03), but had equivalent Charlson comorbidity index, tumor grades, and rates of prior radiotherapy. Relative to IPP placement alone, men were more likely to undergo DI if treated with adjuvant or salvage radiotherapy. The incidence of complications within 30 and 90 days of prosthetic implantation did not differ between groups. Long-term device survival on Kaplan-Meier analysis was not impacted by DI relative to single device implantation with median follow-up of 61 months. CONCLUSION: Combined AUS and IPP placement does not adversely affect perioperative complications or device survival relative to placement of either device alone.


Subject(s)
Penile Prosthesis , Postoperative Complications/epidemiology , Prostatectomy , Prosthesis Failure , Urinary Sphincter, Artificial , Aged , Aged, 80 and over , Humans , Male , Penile Implantation , Prosthesis Implantation/methods , Risk Assessment , Time Factors
10.
Urology ; 124: 57-61, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29421299

ABSTRACT

OBJECTIVE: To determine whether statin intake affects nephrolithiasis risk, and whether higher lipid levels correlate with stone risk. Dyslipidemia is a known independent risk factor for urolithiasis, and emerging evidence suggests common biological pathways. Previous work has suggested that statins protect against new stone formation, but these findings have not been verified by other investigators. METHODS: We queried our Institution's Electronic Data Warehouse for all patients who were newly diagnosed with hyperlipidemia between 2009 and 2011, and had never taken a statin drug. These patients' clinical outcomes were followed until 2015, to assess whether they had been newly prescribed statins and whether they had developed symptomatic urolithiasis. Patient demographics, stone risk factors, prescription data, and serum lipid values were collected. RESULTS: A total of 101,259 patients met inclusion criteria, 47.8% of whom received a statin prescription during the study period. Patients prescribed statins were significantly older, had a greater likelihood of osteoporosis, hemiplegia, immobility, and more likely to take a thiazide diuretic. Patients without a history of urolithiasis who were started on statin therapy were significantly less likely to develop new stones than patients not taking statins. This protective effect was even greater in patients with a history of stone disease. Lipid parameters (low-density lipoprotein, triglyceride, cholesterol) were lower in the statin-treated group, suggesting overall compliance with these medications. CONCLUSION: Our data confirm previous work that statins protect against urinary stone formation; however, the underlying mechanism seems to be distinct from statins' lipid-lowering effect.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Kidney Calculi/prevention & control , Female , Follow-Up Studies , Humans , Hyperlipidemias/complications , Kidney Calculi/epidemiology , Kidney Calculi/etiology , Male , Middle Aged , Risk Assessment
11.
J Robot Surg ; 13(2): 293-299, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30062641

ABSTRACT

To evaluate trends in contemporary robotic surgery across multiple organ sites as they relate to robotic prostatectomy volume. We queried the National Cancer Database for patients who underwent surgery from 2010 to 2013 for prostate, kidney, bladder, corpus uteri, uterus, cervix, colon, sigmoid, rectum, lung and bronchus. The trend between volumes of robotic surgery for each organ site was analyzed using the Cochran-Armitage test. Multivariable models were then created to determine independent predictors of robotic surgery within each organ site by calculating the odds ratio with 95% CI. Among the 566,399 surgical cases analyzed, 35.1% were performed using robot assistance. Institutions whose robotic prostatectomy volume was in the top 75 percentile compared to the bottom 25 percentile performed a larger percentage of robotic surgery on the following sites: kidney 32.6 vs. 28.8%, bladder 23.6 vs. 18.6%, uterus 52.5 vs. 47.7%, cervix 43.5 vs. 39.2%, colon 3.2 vs. 2.9%, rectum 10.7 vs. 8.9%, and lung 7.3 vs. 6.8% (all p < 0.0001). It appears that increased trends toward robotic surgery in urology have lead to increased robotic utilization within other surgical fields. Future analysis in benign utilizations of robotic surgery as well as outcome data comparing robotic to open approaches are needed to better understand the ever-evolving nature of minimally invasive surgery within the United States.


Subject(s)
Databases as Topic , Neoplasms/surgery , Procedures and Techniques Utilization/statistics & numerical data , Robotic Surgical Procedures/statistics & numerical data , Robotic Surgical Procedures/trends , Databases, Factual , Female , Humans , Male , Minimally Invasive Surgical Procedures/methods , Minimally Invasive Surgical Procedures/statistics & numerical data , Minimally Invasive Surgical Procedures/trends , Multivariate Analysis , Prostatectomy/methods , Prostatectomy/statistics & numerical data , Prostatectomy/trends , Robotic Surgical Procedures/instrumentation , United States/epidemiology , Urologic Surgical Procedures/methods , Urologic Surgical Procedures/statistics & numerical data , Urologic Surgical Procedures/trends
12.
World J Urol ; 36(6): 939-945, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29383481

ABSTRACT

PURPOSE: To assess population-based trends in artificial urinary sphincter (AUS) placement after prostatectomy and determine the effect of timing on device survival and complications. METHODS: We identified patients who underwent prostatectomy and AUS placement in SEER-Medicare from 2002 to 2011. We analyzed factors affecting the time of reoperation from AUS implantation and prostatectomy using multivariable Cox proportional hazard models. RESULTS: In total, 841 men underwent AUS placement at a median 23 months after prostatectomy. Patients who underwent reoperation (28.5%) had higher clinical stage, more likely underwent open prostatectomy, or had prior sling placement (p < 0.03). There were no differences in rates of diabetes, smoking status, prior radiation therapy, or Charlson Comorbidity Index between those requiring reoperation vs. not (all p > 0.15). Patients with AUS placement > 15 months after prostatectomy (75%) initially experienced less need for operative reinterventions. Patients with later AUS placement were significantly more likely to have received radiation therapy [22.9 vs. 3.8% (p < 0.01)]. Nonetheless, late implantation was confirmed to be protective on multivariate analysis during the first 5 years after AUS placement [HR 0.79 (95% CI 0.67-0.92); p < 0.01]. Factors independently associated with a shorter interval time until reoperation included history of radiation [HR 1.93 (95% CI 1.33-2.80); p < 0.01] and history of prior sling [HR 1.70 (95% CI 1.08-2.68); p = 0.02]. Even for patients who underwent radiation therapy, delayed AUS implantation reduced reoperative risk. CONCLUSIONS: Late AUS implantation in the Medicare population is associated with prolonged device survival initially, while radiation and prior sling surgery predict for earlier reoperation. Patients with delayed AUS implantation experience less immediate complications. Further work is required to identify patient-specific factors which may explain variability in timing for AUS.


Subject(s)
Prostatectomy/statistics & numerical data , Prostatic Neoplasms/surgery , Prosthesis Failure , Urinary Sphincter, Artificial , Aged , Aged, 80 and over , Humans , Male , Medicare/statistics & numerical data , Postoperative Complications/etiology , Postoperative Complications/therapy , Proportional Hazards Models , ROC Curve , Reoperation , Retrospective Studies , SEER Program , Time Factors , Treatment Outcome , United States , Urinary Incontinence/etiology , Urinary Incontinence/therapy , Urinary Incontinence, Stress
13.
Urology ; 109: 32-37, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28801218

ABSTRACT

OBJECTIVE: To evaluate the Urological resident's attitude and experience with surgical simulation in residency education using a multi-institutional, multi-modality model. MATERIALS AND METHODS: Residents from 6 area urology training programs rotated through simulation stations in 4 consecutive sessions from 2014 to 2017. Workshops included GreenLight photovaporization of the prostate, ureteroscopic stone extraction, laparoscopic peg transfer, 3-dimensional laparoscopy rope pass, transobturator sling placement, intravesical injection, high definition video system trainer, vasectomy, and Urolift. Faculty members provided teaching assistance, objective scoring, and verbal feedback. Participants completed a nonvalidated questionnaire evaluating utility of the workshop and soliciting suggestions for improvement. RESULTS: Sixty-three of 75 participants (84%) (postgraduate years 1-6) completed the exit questionnaire. Median rating of exercise usefulness on a scale of 1-10 ranged from 7.5 to 9. On a scale of 0-10, cumulative median scores of the course remained high over 4 years: time limit per station (9; interquartile range [IQR] 2), faculty instruction (9, IQR 2), ease of use (9, IQR 2), face validity (8, IQR 3), and overall course (9, IQR 2). On multivariate analysis, there was no difference in rating of domains between postgraduate years. Sixty-seven percent (42/63) believe that simulation training should be a requirement of Urology residency. Ninety-seven percent (63/65) viewed the laboratory as beneficial to their education. CONCLUSION: This workshop model is a valuable training experience for residents. Most participants believe that surgical simulation is beneficial and should be a requirement for Urology residency. High ratings of usefulness for each exercise demonstrated excellent face validity provided by the course.


Subject(s)
Internship and Residency , Models, Educational , Simulation Training , Urology/education , Attitude of Health Personnel , Self Report , Time Factors
14.
Urol Oncol ; 35(6): 322-327, 2017 06.
Article in English | MEDLINE | ID: mdl-28065502

ABSTRACT

OBJECTIVE: To determine trends in neoadjuvant and adjuvant chemotherapy use for upper tract urothelial cancer and assess its effects on survival. MATERIALS AND METHODS: We identified all patients diagnosed with upper tract urothelial cancer who underwent surgical treatment in the SEER-Medicare database from 2002 to 2011. We collected and analyzed patient demographic, clinical, and pathologic characteristics. We strictly defined neoadjuvant and adjuvant chemotherapy and studied patients who met such criteria. Multivariable Cox proportional hazards models identified were used to identify independent predictors of overall and cancer-specific survival. RESULTS: A total of 3,432 patients met inclusion criteria, and their median age was 77 years. Overall, 86.4% of patients underwent surgery alone, 1.8% received neoadjuvant chemotherapy plus surgery, and 11.8% underwent surgery and adjuvant chemotherapy. Neoadjuvant chemotherapy use increased during the study period. Gemcitabine, carboplatin, cisplatin, and paclitaxel were the most commonly used agents. Cancer-specific survival at 5 years was 65.0% (95% CI: 63.2%-66.8%). Cox proportional hazards modeling controlling for sex, race, year of diagnosis, location, and pathologic stage revealed that higher pathologic nodal stage, tumor size>3cm, increased age, and carcinoma in situ predicted for worse survival. CONCLUSION: Age, nodal stage, and tumor size>3cm predict for worse cancer-specific survival. Neoajduvant chemotherapy is underused.


Subject(s)
Urologic Neoplasms/drug therapy , Urologic Neoplasms/therapy , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Female , Humans , Male , Neoadjuvant Therapy , Survival Analysis , Urologic Neoplasms/pathology
15.
Urology ; 95: 47-53, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27233928

ABSTRACT

OBJECTIVE: To determine the variance in computeed tomography (CT) radiation measured via dose-length product (DLP) and effective dose (ED) during stone protocol CT scans. METHODS: We retrospectively examined consecutive records of patients receiving stone protocol diagnostic CT scans (n = 1793) in 2010 and 2014 in our health system. Patient age, body mass index (BMI), and gender were recorded, along with the hospital, machine model, year, DLP, and ED of each scan. Multivariate regression was performed to identify predictive factors for increased DLP. We also collected data on head (n = 837) CT scans to serve as a comparison. RESULTS: For stone CT scans, mean patient age was 55.1 ± 18.4 years with no significant difference in age (P=.2557) or BMI (P=.1794) between 2010 and 2014. Gender, BMI, and machine model were independent predictors of radiation dosage (P < .0001). Within each BMI class, there was an inexplicable 6-fold variation in the ED for the same imaging test when comparing the lowest and highest CT dose patients. There was no significant change in DLP over time for stone CT scans, but head scan patients in 2014 received lower radiation doses than those in 2010 (P < .0001). Low-dose scans for renal colic (defined as <4 mSv) were underutilized. Substantial variation exists for head scan radiation doses. CONCLUSION: Our data demonstrate large variations in diagnostic CT radiation dosage. Such differences within a single institution suggest similar trends elsewhere, warranting more stringent dosage guidelines and regulations for diagnostic CT scans within institutions.


Subject(s)
Radiation Dosage , Radiation Exposure/statistics & numerical data , Tomography, X-Ray Computed , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Young Adult
16.
Am J Obstet Gynecol ; 213(5): 691.e1-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26215329

ABSTRACT

OBJECTIVE: The purpose of this study was to determine the cost-effectiveness of serial stenting vs ureteroscopy for treatment of urolithiasis during pregnancy as a function of gestational age (GA) at diagnosis. STUDY DESIGN: We built decision analytic models for a hypothetical cohort of pregnant women who had received a diagnosis of symptomatic ureteral calculi and compared serial stenting to ureteroscopy. We assumed ureteral stent replacement every 4 weeks during pregnancy, intravenous sedation for stent placement, and spinal anesthetic for ureteroscopy. Outcomes were derived from the literature and included stent infection, migration, spontaneous kidney stone passage, ureteral injury, failed ureteroscopy, postoperative urinary tract infection, sepsis, and anesthetic complications. Four separate analyses were run based on the GA at diagnosis of urolithiasis. Using direct costs and quality-adjusted life years, we reported the incremental costs and effectiveness of each strategy based on GA at kidney stone diagnosis and calculated the net monetary benefit. We performed 1-way and Monte-Carlo sensitivity analyses to assess the strength of the model. RESULTS: Ureteroscopy was less costly and more effective for urolithiasis, irrespective of GA at diagnosis. The incremental cost of ureteroscopy increased from -$74,469 to -$7631, and the incremental effectiveness decreased from 0.49 to 0.05 quality-adjusted life years for a kidney stone diagnosed at 12 and 36 weeks of gestation, respectively. The net monetary benefit of ureteroscopy progressively decreased for kidney stones that were diagnosed later in pregnancy. The model was robust to all variables. CONCLUSION: Ureteroscopy is less costly and more effective relative to serial stenting for urolithiasis, regardless of the GA at diagnosis. Ureteroscopy is most beneficial for women who received the diagnosis early during pregnancy.


Subject(s)
Pregnancy Complications/therapy , Stents , Ureteroscopy , Urolithiasis/therapy , Cost-Benefit Analysis , Decision Support Techniques , Female , Foreign-Body Migration/epidemiology , Humans , Pregnancy , Pregnancy Complications/economics , Stents/economics , Ureteroscopy/adverse effects , Ureteroscopy/economics , Urolithiasis/economics
17.
Minim Invasive Ther Allied Technol ; 21(5): 320-8, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22332891

ABSTRACT

BACKGROUND: The current gold standard of bladder cancer surveillance, endoscopic visualization, is manually manipulated and still has significant room for improvement in performance and controls. METHODS: This paper reports our developments toward automated bladder surveillance that employs a shape memory alloy-based machine-controlled scanning mechanism. In conjunction with the electro-mechanical advances, we use modified commercial post-processing computer vision software capable of converting cystoscopic video of the bladder into stitched panoramas. RESULTS: Experimental results conducted on a synthetic bladder demonstrate that this computer-aided scanning tool can help 82% of the entire bladder surface being scanned. Although the panoramic stitching algorithm increases the field of view and generates reasonable results in many cases, some image matching failures result in incompleteness in its full panoramic reconstruction. CONCLUSION: Our current study ensures that the automated steering mechanism can follow the desired trajectory to scan the surface of the bladder but must be improved. The current reconstruction algorithm needs further modification. Our methodology may constitute a first step in suggesting a new automated and computer-aided bladder surveillance system.


Subject(s)
Cystoscopy/methods , Lasers , Urinary Bladder Neoplasms/diagnosis , Urinary Bladder/pathology , Algorithms , Humans , Image Processing, Computer-Assisted , Research Design , Software , Time Factors , Urinary Bladder Neoplasms/pathology
18.
J Med Device ; 3(1): 11004, 2009 Mar 01.
Article in English | MEDLINE | ID: mdl-20011075

ABSTRACT

Given the advantages of cystoscopic exams compared with other procedures available for bladder surveillance, it would be beneficial to develop an improved automated cystoscope. We develop and propose an active programmable remote steering mechanism and an efficient motion sequence for bladder cancer detection and postoperative surveillance. The continuous and optimal path of the imaging probe can enable a medical practitioner to readily ensure that images are produced for the entire surface of the bladder in a controlled and uniform manner. Shape memory alloy (SMA) based segmented actuators disposed adjacent to the distal end of the imaging probe are selectively activated to bend the shaft to assist in positioning and orienting the imaging probe at a plurality of points selected to image all the interior of the distended bladder volume. The bending arc, insertion depth, and rotational position of the imaging probe are automatically controlled based on patient-specific data. The initial prototype is tested on a 3D plastic phantom bladder, which is used as a proof-of-concept in vitro model and an electromagnetic motion tracker. The 3D tracked tip trajectory results ensure that the motion sequencing program and the steering mechanism efficiently move the image probe to scan the entire inner tissue layer of the bladder. The compared experimental results shows 5.1% tip positioning error to the designed trajectory given by the simulation tool. The authors believe that further development of this concept will help guarantee that a tumor or other characteristic of the bladder surface is not overlooked during the automated cystoscopic procedure due to a failure to image it.

19.
J Endourol ; 23(3): 421-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19260799

ABSTRACT

OBJECTIVE: We aimed to study differences in reablation rates, modality utilization, and outcomes after renal tumor cryoablation (CA) and radiofrequency ablation (RFA), stratified by medical specialty. METHODS: A literature review was performed to identify papers reporting renal RFA and CA results. Patient demographics and clinical and pathological variables were collected, as were ablation success and salvage treatment rates. RESULTS: Interventional radiologists (IR) reported more experience with renal RFA than with CA (31.4% v 11.3% of all reported cases, p < 0.001). However, the majority of renal RFA and CA are performed by urologists. The percutaneous approach was used far more often with RFA than with CA, reflecting this preference by radiologists (80.9% v 23.4%, p < 0.01). The mean tumor size, cancer-specific survival rates, mean follow-up duration, and salvage nephrectomy rates were not statistically different between CA and RFA. Tumor reablation rates were significantly higher for RFA than for CA (7.4% v 0.9%, p = 0.009). RFA reablation rate correlated closely to surgeon specialty, such that 72% of reablations were reported by IR, while only 28% were performed primarily by urologists (p < 0.0001). This was despite IR being primary surgeons in only 31.4% of first tumor ablations. Salvage nephrectomy was performed more after CA than after renal RFA, probably because 89% of CA were done by urologists. There were no reablations in the laparoscopically approached cases. CONCLUSIONS: Cancer-specific outcomes after renal tumor CA and RFA are similar. However, RFA has required more reablations to achieve 95% cancer-specific survival rates. IR reported more experience with RFA, and urologists reported more experience with CA. Overall, RFA and CA reablation rates are significantly higher when a percutaneous approach is used and seemed to correlate with surgeon specialty.


Subject(s)
Catheter Ablation/methods , Cryosurgery/methods , Delivery of Health Care/statistics & numerical data , Kidney Neoplasms/surgery , Medicine , Nephrectomy/methods , Specialization , Demography , Humans , Practice Patterns, Physicians'/statistics & numerical data
20.
BJU Int ; 102(8): 1005-7, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18564131

ABSTRACT

OBJECTIVE: To assess the functional and histological effects of a bovine thrombin topical haemostatic agent used clinically to aid in surgical haemostasis (FloSeal(TM), Baxter International Inc., Deerfield, IL, USA) on the cavernous nerves in a canine model of survival, as there are concerns that the fibrotic/inflammatory response to this product could affect neural function. MATERIALS AND METHODS: In phase I, nine adult male dogs had the bilateral neurovascular bundles (NVBs) dissected. A small intravenous catheter placed directly into the erectile bodies of the penis was used to record the intracorporal pressure (ICP). Erection was induced by electrical stimulation of the NVB on each side. After intraoperative randomization to treatment or control, 5 mL of FloSeal was unilaterally applied along the NVB on the treatment side. In phase II, after 2 weeks of survival, both control and treatment NVB were again dissected and re-stimulated to produce an erectile response. The mean arterial pressure and ICP were recorded. The prostate and the NVBs were then removed for histological analysis. RESULTS: All dogs achieved erections after electrical stimulation on both the control and treatment side. There was no statistically significant difference in absolute ICP, pressure increase from baseline or systemic pressure after stimulating the NVB on the treatment side between phases I and II. Histological analysis showed a giant-cell reaction around the FloSeal granules and mild focal perineural oedema, but the cavernous nerves were otherwise normal in appearance. CONCLUSION: In this short-term functional study, FloSeal did not adversely affect cavernous nerve function, measured as the erectile response to electrical stimulation. We found no evidence contraindicating its use during radical prostatectomy.


Subject(s)
Erectile Dysfunction/chemically induced , Gelatin Sponge, Absorbable/adverse effects , Hemostatics/adverse effects , Penis/physiology , Prostate , Prostatectomy , Administration, Topical , Animals , Dogs , Gelatin Sponge, Absorbable/therapeutic use , Hemostatics/therapeutic use , Male , Penile Erection/physiology , Penis/blood supply , Penis/innervation , Prostate/blood supply , Prostate/innervation , Prostate/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...